• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立大麻提取物新药代码。最终规则。

Establishment of a New Drug Code for Marihuana Extract. Final rule.

出版信息

Fed Regist. 2016 Dec 14;81(240):90194-6.

PMID:28000787
Abstract

The Drug Enforcement Administration is creating a new Administration Controlled Substances Code Number for "Marihuana Extract." This code number will allow DEA and DEA-registered entities to track quantities of this material separately from quantities of marihuana. This, in turn, will aid in complying with relevant treaty provisions. Under international drug control treaties administered by the United Nations, some differences exist between the regulatory controls pertaining to marihuana extract versus those for marihuana and tetrahydrocannabinols. The DEA has previously established separate code numbers for marihuana and for tetrahydrocannabinols, but not for marihuana extract. To better track these materials and comply with treaty provisions, DEA is creating a separate code number for marihuana extract with the following definition: "Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Extracts of marihuana will continue to be treated as Schedule I controlled substances.

摘要

美国缉毒局正在为“大麻提取物”创建一个新的管制物质管理编号。这个编号将使缉毒局和注册的缉毒局实体能够分别追踪该物质的数量与大麻的数量。这反过来将有助于遵守相关条约规定。在联合国管理的国际毒品管制条约下,大麻提取物的管制规定与大麻和四氢大麻酚的管制规定存在一些差异。缉毒局此前已为大麻和四氢大麻酚设立了单独的编号,但未为大麻提取物设立。为了更好地追踪这些物质并遵守条约规定,缉毒局正在为大麻提取物创建一个单独的编号,其定义如下:“指从大麻属的任何植物中提取的含有一种或多种大麻素的提取物,但不包括从该植物中获得的分离树脂(无论是粗制的还是纯化的)。”大麻提取物将继续被视为附表一管制物质。

相似文献

1
Establishment of a New Drug Code for Marihuana Extract. Final rule.建立大麻提取物新药代码。最终规则。
Fed Regist. 2016 Dec 14;81(240):90194-6.
2
Applications To Become Registered Under the Controlled Substances Act To Manufacture Marijuana To Supply Researchers in the United States. Policy statement.根据《受控物质法》申请注册以制造大麻并供应给美国研究人员。政策声明。
Fed Regist. 2016 Aug 12;81(156):53846-8.
3
Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.管制物质清单:丁丙诺啡从V类重新划分为III类。最终规则。
Fed Regist. 2002 Oct 7;67(194):62354-70.
4
Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
Fed Regist. 1991 Jun 3;56(106):25025-7.
5
Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.取消含有附表一化学品麻黄碱和/或伪麻黄碱的化学混合物的豁免规定。最终规则。
Fed Regist. 2008 Jul 10;73(133):39611-4.
6
Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
Fed Regist. 2007 Dec 3;72(231):67850-2.
7
Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.管制物质清单:将α-甲基色胺和5-甲氧基-N,N-二异丙基色胺列入《管制物质法》附表一。最终规则。
Fed Regist. 2004 Sep 29;69(188):58950-3.
8
Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements. Final order.《受管制物质清单:将某些含大麻二酚的FDA批准药物列入第五类;对许可要求的相应变更。最终命令》
Fed Regist. 2018 Sep 28;83(189):48950-3.
9
Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.管制物质清单:将佐匹克隆列入附表四。最终规则。
Fed Regist. 2005 Apr 4;70(63):16935-7.
10
Classification of three steroids as schedule III anabolic steroids under the Controlled Substances Act. Final rule.
Fed Regist. 2009 Dec 4;74(232):63603-10.

引用本文的文献

1
Young adults' knowledge, perceptions and use of cannabidiol products: a mixed-methods study.年轻人对大麻二酚产品的认知、看法和使用情况:一项混合方法研究。
Health Educ Res. 2022 Nov 21;37(6):379-392. doi: 10.1093/her/cyac030.
2
Cannabidiol Knowledge, Perceptions, and Use Among Young Adults in 6 U.S. Metropolitan Areas.美国6个大都市地区年轻人对大麻二酚的了解、认知与使用情况
Cannabis Cannabinoid Res. 2023 Dec;8(6):1140-1149. doi: 10.1089/can.2022.0029. Epub 2022 Jul 26.
3
Cannabidiol Signaling in the Eye and Its Potential as an Ocular Therapeutic Agent.
眼部的大麻素信号及其作为眼部治疗药物的潜力。
Cell Physiol Biochem. 2021 May 14;55(S5):1-14. doi: 10.33594/000000371.
4
Regulatory Status of Cannabidiol in the United States: A Perspective.大麻二酚在美国的监管状况:一种视角。
Cannabis Cannabinoid Res. 2018 Sep 27;3(1):190-194. doi: 10.1089/can.2018.0030. eCollection 2018.
5
A Cross-Sectional Study of Cannabidiol Users.大麻二酚使用者的横断面研究。
Cannabis Cannabinoid Res. 2018 Jul 1;3(1):152-161. doi: 10.1089/can.2018.0006. eCollection 2018.